Cryotherapy for prostate cancer: ready for prime time?

Area of Science:

• Urology
• Oncology
• Minimally Invasive Surgery

Background:

• Concerns regarding prostate cancer overtreatment highlight the need for less invasive therapeutic options.
• Cryotherapy has evolved significantly, necessitating an update on its current evidence base for clinical practice.

Purpose of the Study:

• To review the current evidence supporting the use of cryotherapy in prostate cancer management.
• To inform clinicians about the efficacy and safety of modern cryotherapy techniques.

Main Methods:

• Review of technical advancements in cryotherapy delivery systems.
• Analysis of data from the Cryotherapy On-Line Data Registry (COLD Registry) for biochemical outcomes.
• Comparison of cryotherapy outcomes with radiation therapy from recent trials and literature.

Main Results:

• Modern argon-based cryotherapy demonstrates low complication rates: <5% incontinence, ≤0.5% rectal fistula.
• 5-year biochemical disease-free survival rates range from 91% (low-risk) to 62% (high-risk) per COLD Registry data.
• Cryotherapy shows comparable biochemical outcomes to radiation therapy, with a higher rate of negative post-treatment biopsies (87-98%).
• Focal cryotherapy exhibits promising potency rates (71-90%) and warrants further investigation.

Conclusions:

• Whole-gland cryotherapy is a viable treatment option due to favorable outcomes, low complications, and high rates of negative biopsies.
• Cryotherapy's long-term biochemical results are comparable to radiation monotherapy, with potentially superior biopsy results.
• Clinicians should consider cryotherapy as an alternative to initial radiation therapy for prostate cancer.